SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Political uncertainty ahead of the midterm elections and debate over the Iran conflict dominate discussion, with traders linking war and cost-of-living concerns to market pressure and DJTs decline. Bearish views prevail, though some speculate a peace deal or Republican win could improve sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody for menopausal hot flashes: traders are discussing its positive Phase 2 results and additional conference data while watching for longer-term durability results and clarity on a Phase 3 path. Bulls view the program as validation of AbCelleras pipeline, while skeptics say the latest presentation added little beyond known results and want more concrete clinical updates.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports of advanced talks to acquire Lumentum have driven attention, with traders worried the large deal could require substantial share dilution or debt and weigh on Marvell. Some see strategic value in combining Marvells AI networking chips with Lumentums optical technology, but the talks remain unconfirmed and the market reaction has been sharply negative.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas negative S&P outlook, tied to heavy AI infrastructure spending and uncertainty about free cash flow, is driving concern alongside fears that planned stock sales could dilute shareholders. Traders debate whether strong advertising growth and potential AI monetization can justify the investment, with some viewing the selloff as a buying opportunity.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention as natural-gas weakness and repeated lows collide with hopes for a winter-weather rebound. Traders disagree over whether colder forecasts and tighter storage could spark a bounce, while others point to mild-weather expectations, ample supply, and the ETFs leverage and futures-roll decay as risks.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y

DVA's Q3 earnings surge 52.2% as revenues rise 4.6%, fueled by strong kidney care and international growth despite rising costs and margin pressure.

DaVita Q3 2026 Earnings Call Transcript

DaVita (NYSE:DVA) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...

DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of +1.06% and +1.34%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

DaVita Inc. 3rd Quarter 2026 Results

DaVita Inc. 3rd Quarter 2026 Results DaVita Inc. 3rd Quarter 2026 ResultsPR NewswireDENVER, Oct. 29, 2026 DENVER, Oct. 29, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September30, 2026.Financial and operating highlights for the...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVAPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is...

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?

DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.

DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know

DaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?

DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference CallPR NewswireDENVER, Oct. 19, 2026 DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announcedtoday that it will hold its quarterly conference call to discuss...

DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know

DaVita HealthCare (DVA) closed at $187.25 in the latest trading session, marking a -1.01% move from the prior day.

• Reported GAAP EPS of $3.82 up 52.19% YoY
• Reported revenue of $3.58B up 4.62% YoY
• DaVita's current 2026 guidance is adjusted operating income of $2.18B, adjusted diluted net income per share of $14.30$15.20, and free cash flow of $1B.

DaVita's Q3 operating margin was below Q2, patient care costs per treatment were higher, and commercial-payor profit concentration faces continued downward pressure on average realized payment rates.

DaVita reported higher Q3 2026 revenue and diluted EPS than Q3 2025, normalized non-acquired treatment growth of 0.4%, and 80,800 risk-based integrated-care patients representing $6.4B annualized medical spend.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

Why Did DaVita Stock Jump 15% After Hours Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The company beat Q4 earnings and issued 2026 EPS guidance above consensus.</li><li>Q4 IKC adjusted operating income was $46 million, with full-year results lifted by stronger-than-expected shared savings from&nbsp;the final 2024 reconciliation.</li><li>DaVita expects flat treatment volumes in 2026, noting that a return to 2% or higher growth will depend on improved clinical outcomes.</li></ul><p>Shares of DaVita Inc. jumped about 15% in extended trading&nbsp;on Monday after the dialysis service provider topped fourth-quarter (Q4) earnings estimates and said its Integrated Kidney Care (IKC) unit hit profitability a year earlier than planned.</p><h2 class="st-heading-2"><strong>Earnings And 2026 Outlook Beat Expectations</strong></h2><p>DaVita reported Q4 adjusted earnings per share (EPS) of $3.40, beating consensus of $3.19, on revenue of $3.62 billion, also above estimates of $3.51 billion.&nbsp;</p><p>For 2026, the company forecast adjusted EPS of $13.6-$15, versus consensus of $12.74, along with adjusted operating income growth of $2.085 billion-$2.235 billion and free cash flow of $1-$1.25 billion.</p><h2 class="st-heading-2"><strong>Integrated Kidney Care Turns Profitable Ahead Of Plan</strong></h2><p>DaVita said IKC achieved full-year profitability in 2025, a year ahead of its original 2026 target. Q4 IKC adjusted operating income was $46 million, while full-year results benefited from stronger-than-expected shared savings tied to&nbsp;the final reconciliation of 2024 performance. The company said the milestone validates its clinical care model, contracting structure, and technology-enabled platform, and expects to deliver $20 million&nbsp;in incremental IKC operating income growth in 2026.</p><h2 class="st-heading-2"><strong>IKC Patients See Lower Costs, Better Survival</strong></h2><p>The company said IKC patients were 35% more likely to start dialysis with permanent vascular access and incurred three times lower costs in the first 180 days of treatment. The company cited fewer bloodstream infections, higher vaccination rates, better adherence, and fewer missed treatments.&nbsp;</p><p>Vaccinated patients&nbsp;had a 9% lower risk of hospitalization and a 27% lower risk of mortality. DaVita also said GLP-1 drugs and advanced dialysis technologies could reduce mortality over time.</p><h2 class="st-heading-2"><strong>DaVita Braces For ACA Hit, Eyes Medicare Boost</strong></h2><p>DaVita expects treatment volume to be roughly flat in 2026, noting that a return to 2% or higher growth will depend on improved clinical outcomes, with benefits likely to show up over the next couple of years. The company also flagged a $40 million headwind in 2026 from changes to ACA premium support, noting the impact is expected to increase in 2027 before easing thereafter.</p><p>At the same time, DaVita pointed to a potential tailwind in 2027, citing a 6% Medicare Advantage rate increase for end-stage renal disease (ESRD) patients. The company also announced a $200 million minority investment in Elara Caring&nbsp;to expand home-based care and reduce hospitalizations and missed treatments.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for DaVita was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/dva_ss_png_06c11a7684.webp" alt="dva ss.png" width="974" height="143"><figcaption>DVA sentiment and message volume as of February 2 | Source: Stocktwits</figcaption></figure><p>One user said, “This appears way undervalued with those numbers. Single digit multiple to earnings.”</p><p><stembedurl>https://stocktwits.com/Chickenstick1/message/643737411</stembedurl></p><p>Another user called the update a “nice” earnings report.</p><p><stembedurl>https://stocktwits.com/MaverikIT/message/643738852</stembedurl></p><p><a href="https://stocktwits.com/symbol/DVA">DaVita’s stock</a> has declined 37% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the DaVita Inc company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

DaVita said its integrated kidney care unit hit full-year profitability in 2025, a year ahead of its original 2026 target. 

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$187.50
Prev Close	$193.31
Open	$175.00
Dividend Yield	0.00%
50-Day Moving Average	$181.40
Beta	0.35
Avg. Volume	718,085.90
PE Ratio	14.18

52-Week High	$247.49
52-Week Low	$101.00
Market Capitalization	$11.79B
EPS (Annual)	$9.51
Price to Book	-20.11
Revenue Per Employee	$174,911.14

Feed

News

Sentiment

Earnings

Fundamentals

Info

DVA Fundamentals